ClinicalTrials.gg
CompletedNCT05926466DECISIONUpdated Oct 5, 2026

BTZ-043 Dose Evaluation in Combination and Selection

A Phase 2 interventional study of BTZ-043 and Bedaquiline in Tuberculosis, Pulmonary and Other Specified Pulmonary Tuberculosis, sponsored by Michael Hoelscher. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Michael Hoelscher · Phase 2, Interventional, and Treatment

How we know

Updated Oct 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.

Enrollment
47th of 67
92 · median 122
Started
2023
with 6 others
Phase 2
49 of 78
8 open now
Registered
66th of 78
by date
Lead sponsor
6 of 78
Michael Hoelscher

Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 47th largest by enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2023, is one of 49 in phase 2, and was the 66th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Tuberculosis, Pulmonary with a site in South Africa, or all of them as a file.
02

Study summary

This is a phase 2B, open label study, that will compare the safety and efficacy of three experimental regimens consisting of bedaquiline and delamanid in combination with different doses of BTZ-043, a novel antibiotic, in adult participants with newly diagnosed, drug-sensitive pulmonary tuberculosis. Participants will be assigned to receive either one of the three BTZ-043-containing regimens or a comparator regimen consisting of bedaquiline, delamanid and moxifloxacin. The objective is to find the optimal dose of BTZ-043 with the highest efficacy and safety to be used in subsequent studies.

Read the detailed description

This open label, phase 2B, randomized controlled study will evaluate three experimental arms containing different doses of BTZ-043 in combination with bedaquiline and delamanid, in adult subjects with newly diagnosed, drug-sensitive pulmonary tuberculosis, in comparison with bedaquiline, delamanid and moxifloxacin, administered over 16 weeks. A total of 90 adult (≥ 18 years of age) participants will be enrolled. In case of a high number of dropouts or non-evaluable participants, it may be necessary to recruit more participants into the study.

The participants will be randomly allocated to one of the three BTZ-containing experimental regimens or the moxifloxacin-containing comparator regimen:

Arm 1: bedaquiline, delamanid, BTZ-043 500 mg (BDT500) Arm 2: bedaquiline, delamanid, BTZ-043 1000 mg (BDT1000) Arm 3: bedaquiline, delamanid, BTZ-043 1500 mg (BDT1500) Arm 4: bedaquiline, delamanid, moxifloxacin (BDM) In all arms, bedaquiline will be dosed at 400 mg once daily for 2 weeks, followed by 100 mg once daily for 14 weeks and delamanid will be dosed at 300 mg once daily for 16 weeks. Moxifloxacin will be dosed at 400 mg once daily in the comparator arm. After completion of 16 weeks of treatment, all participants will receive 8 weeks of continuation therapy with Rifampicin and Isoniazid.

03

Conditions studied

  • Tuberculosis, Pulmonary
  • Other Specified Pulmonary Tuberculosis

Keywords

  • Tuberculosis
  • BTZ-043
  • Bedaquiline
  • Delamanid
  • Moxifloxacin
  • Safety
  • Tolerability
  • Pharmacokinetics (PK)
  • Benzothiazinones
  • Pulmonary Tuberculosis
  • Dose-finding
  • Antitubercular agents
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written, prior to all trial-related procedures, including testing.
  • Male or female, aged 18 up to (and including) 64 years.
  • Body weight (in light clothing and with no shoes) within the range of 30 to 100kg and within the range of 15 to 40kg/m2.
  • Newly diagnosed, previously untreated current episode of drug-susceptible pulmonary TB (presence of MTB complex with rapid molecular test result confirming susceptibility to rifampicin and isoniazid such as "GeneXpert" and/or "HAIN MTBDR plus").
  • ≥ 1 sputum sample from concentrated spot sputum positive in GeneXpert MTB/RIF Ultra®, with semi-quantitative result at least "medium" or higher.
  • FEMALE PARTICIPANTS: Inability to conceive AND/OR inability of partner(s) to father children OR consent to use effective methods of when engaging in heterosexual intercourse, as defined below:

    a. Non-: i) Bilateral oophorectomy AND/OR hysterectomy OR bilateral tubal ligation more than 12 months ago, AND/OR has been with a history of no menses for at least 12 consecutive months as per medical history.

ii) Sexual partner(s) of female participant: vasectomy OR bilateral orchidectomy at least three months prior to screening as per medical history.

b. Effective contraception methods: i) Two methods, including methods used by patient's sexual partner(s). At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of BTZ-043.

- MALE PARTICIPANTS: Inability to father children AND/OR inability of partner(s) to conceive, OR consent to use effective methods of contraception when engaging in heterosexual intercourse, as defined below:

c. Non-childbearing potential: i) Sexual partner(s) of male participant: Bilateral oophorectomy AND/OR hysterectomy OR bilateral tubal ligation more than 12 months ago, AND/OR has been postmenopausal with a history of no menses for at least 12 consecutive months as per medical history.

ii) Vasectomy OR bilateral orchidectomy at least three months prior to screening as per medical history.

iii) Female pregnant sexual partner of a male participant: agree to use at least one barrier method.

iv) Male sexual partner of male participant: agree to use at least one barrier method for at least until 12 weeks after the last dose of BTZ-043 for protection of the partner.

d. Effective contraception methods: ii) Two methods, including methods used by patient's female sexual partner(s). At least one must be a barrier method. Effective contraception must be ensured for at least 16 weeks after the last dose of BTZ-043

Exclusion criteria

Exclusion Criteria:

  • Circumstances that raise doubt about free, unconstrained consent to study participation (e.g. in a prisoner or person suffering from an intellectual disability).
  • Poor general condition, where delay in treatment cannot be tolerated, or death within three months is likely, as assessed by the investigator.
  • Poor social condition which would result in a high likelihood of not completing the trial until the final visit.
  • The patient is pregnant or breast-feeding.
  • The patient is antibody positive (known, or on a test performed at screening), unless:

    1. The patient has a viral load (VL) \< 200 copies/mL on a test performed at screening
    2. The patient has a > 200 cells/mm3 at screening
    3. The patient is experienced on antiretroviral therapy (ART), and is on a combination of tenofovir, lamivudine and dolutegravir (TDF/3TC/DTG) for a minimum of 6 months prior to the screening visit.
  • The patient has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are .
  • The patient has received treatment with any other drug within 1 month prior to enrolment, or is planning to be enrolled into other clinical (intervention) trials during participation.
  • The patient has a history of or current evidence of cardiovascular, metabolic, gastrointestinal, neurological, ophthalmological, psychiatric or endocrine diseases, or any other condition, that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:

    1. Clinically significant evidence of severe or extra-thoracic TB (e.g., miliary TB, TB meningitis, excluding limited lymph node involvement)
    2. Serious lung conditions other than TB or significant respiratory impairment in the discretion of the investigator
    3. Peripheral neuropathy (as evaluated by the Brief Peripheral Neuropathy Score).
    4. Significant psychiatric disorder like depression or schizophrenia; especially if treatment for those has ever been required in the last five years or is anticipated to be required.
    5. An established diagnosis of diabetes mellitus.
    6. Cardiovascular disease, such as myocardial infarction, heart failure, coronary heartdisease, arrhythmia, tachyarrhythmia, or pulmonary hypertension.
    7. Current (as measured on two occasions during screening) or history of hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg) on two occasions. Controlled hypertension is permitted if the patients receive only the allowed anti-hypertensives.
    8. Long syndrome or family history of long QT syndrome or sudden death of unknown or cardiac-related cause.
    9. Alcohol or other drug abuse, that is sufficient to significantly compromise the safety or cooperation of the patient, includes substances prohibited by the protocol, or has led to significant organ damage, at the discretion of the investigator. An isolated positive test for cannabinoids does not fulfil this exclusion criterion.
    10. Chronic kidney disease (CKD) or any other history of renal impairment.
  • Any of the following laboratory findings at screening:

    1. serum amino aspartate transferase () and/or alanine aminotransferase (ALT) activity >3x the
    2. serum alkaline phosphatase (ALP) >3x the ULN
    3. serum total level >1.5 times the ULN
    4. estimated (eCrCl) \< 60 mls/min (calculated using the Cockcroft and Gault formula
    5. level \<8.0 g/dL
    6. count \<50,000/mm3
    7. albumin \< 2.8 g/dl
    8. serum potassium \<3.5 mmol/L (not excluded if subsequently corrected)
    9. serum magnesium \< 0.5mmol/L (not excluded if subsequently corrected)
  • Any of the following findings at screening:

    1. QTcF of > 450 milliseconds (ms)
    2. Atrioventricular (AV) block with PR interval > 200 ms
    3. QRS complex > 120 ms
    4. any other changes in the ECG that are clinically relevant as per discretion of the investigator
  • Any of the following regarding concomitant medications at screening:

    1. Previous treatment with first- and anti-TB drugs within the last 3 months prior to screening.
    2. Treatment with any other investigational drug (including vaccines) within 1 month prior to enrolment or enrolment into other clinical (interventional) trials during participation.
    3. Unable or unwilling to only take the allowed concomitant medications for this studyand ensuring an appropriate
    4. Unable or unwilling to abide to the dietary restrictions required in this study
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: Moxifloxacin Moxifloxacin will be dosed at the licensed dose of 400 mg orally once daily for 16 weeks Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks

    Drug: Bedaquiline · Drug: Delamanid · Drug: Moxifloxacin

  • Experimental
    Arm 2

    Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 500 mg orally once daily for 16 weeks

    Drug: BTZ-043 · Drug: Bedaquiline · Drug: Delamanid

  • Experimental
    Arm 3

    Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1000 mg orally once daily for 16 weeks

    Drug: BTZ-043 · Drug: Bedaquiline · Drug: Delamanid

  • Experimental
    Arm 4

    Drug: Bedaquiline Bedaquiline will be dosed at 400 mg orally once daily for the first 2 weeks, followed by 100 mg orally once daily for 14 weeks Drug: Delamanid Delamanid will be dosed at 300 mg orally once daily for 16 weeks Drug: BTZ-043 BTZ-043 will be dosed at 1500 mg orally once daily for 16 weeks

    Drug: BTZ-043 · Drug: Bedaquiline · Drug: Delamanid

Interventions

  • BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.

  • Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.

    Also known as: SIRTURO®

  • DrugOPC-67683Studies of OPC-67683OPC-67683 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.

    Also known as: OPC-67683, Deltyba

  • Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.

    Also known as: Lonxave

06

What researchers measure

Primary outcomes

  1. Time to positivity in BD MGIT liquid culture

    To evaluate which of the BTZ-043 containing experimental arms is superior, the change in mycobacterial load over time on treatment as quantified by time to positivity in BD MGIT 960® (Mycobacterium Growth Tube Indicator) liquid culture described by non-linear mixed-effects methodology

    Time frame: Day 01- Day 112

Secondary outcomes

  1. Time to stable culture conversion to negative in liquid media

    The time on treatment required until a participant achieves the first of two successive visits with negative cultures without an intervening positive culture

    Time frame: Day 01- Day 112

  2. Proportion of participants converting to negative sputum culture in liquid media

    Proportion of participants converting to negative sputum culture in liquid media defined as two consecutive negative cultures without an intervening positive culture) at each time point during treatment

    Time frame: Day 01- Day 112

  3. Frequency of all adverse events (serious and non-serious)

    To assess the frequency, severity, and type of adverse events (AEs), and AE related treatment discontinuations.

    Time frame: Day 01- Day 168

  4. Frequency of adverse events of Grade 3 severity (severe) or higher

    Severity of AEs will be classified following the U.S. National Institutes of Health Common Terminology Criteria for Adverse Events 5.0 (CTCAE). The minimum grade is 1 (Mild) and the maximum grade is 5 (Death related to AE). Higher scores mean a worse outcome

    Time frame: Day 01- Day 168

  5. Frequency of adverse events possibly, probably or definitely related to study drug

    To assess the frequency, severity, and type of adverse events (AEs), and AE related treatment discontinuations.

    Time frame: Day 01- Day 168

  6. Frequency of treatment discontinuations or interruptions related to adverse events/serious adverse event

    To assess the frequency, severity, and type of adverse events (AEs), and AE related treatment discontinuations.

    Time frame: Day 01- Day 168

  7. Changes in ECG intervals of PR, RR, QRS, QT, Fridericia-corrected QT [QTcF]

    • Proportion of participants with QTcF \> 500ms in ECGs on treatment. • Proportion of participants who have a QTcF prolongation of grade 3 or higher

    Time frame: Day 01- Day 168

  8. Area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0-24)

    The pharmacokinetics parameters will be assessed for BTZ-043, bedaquiline and delamanid, and their major metabolites (Arm 2-4), in all participants. Extensive sampling will be done for BTZ-043 at the WK04 visit (Day 28 ± 2 Days) and sparse PK sampling for bedaquiline and delamanid on WK04 (Day 28 ± 2 Days) and WK08 visits (Day 56 ± 2 Days)

    Time frame: Day 28, Day 56

  9. The observed maximum concentration (Cmax)

    The pharmacokinetics parameters will be assessed for BTZ-043, bedaquiline and delamanid, and their major metabolites (Arm 2-4), in all participants. Extensive sampling will be done for BTZ-043 at the WK04 visit (Day 28 ± 2 Days) and sparse PK sampling for bedaquiline and delamanid on WK04 (Day 28 ± 2 Days) and WK08 visits (Day 56 ± 2 Days)

    Time frame: Day 28, Day 56

  10. Time to reach Cmax (Tmax)

    The pharmacokinetics parameters will be assessed for BTZ-043, bedaquiline and delamanid, and their major metabolites (Arm 2-4), in all participants. Extensive sampling will be done for BTZ-043 at the WK04 visit (Day 28 ± 2 Days) and sparse PK sampling for bedaquiline and delamanid on WK04 (Day 28 ± 2 Days) and WK08 visits (Day 56 ± 2 Days)

    Time frame: Day 28, Day 56

  11. Minimum observed plasma concentration 24 hours following the last dose (Cmin)

    The pharmacokinetics parameters will be assessed for BTZ-043, bedaquiline and delamanid, and their major metabolites (Arm 2-4), in all participants. Extensive sampling will be done for BTZ-043 at the WK04 visit (Day 28 ± 2 Days) and sparse PK sampling for bedaquiline and delamanid on WK04 (Day 28 ± 2 Days) and WK08 visits (Day 56 ± 2 Days)

    Time frame: Day 28, Day 56

  12. Apparent oral clearance (Cl/F)

    The pharmacokinetics parameters will be assessed for BTZ-043, bedaquiline and delamanid, and their major metabolites (Arm 2-4), in all participants. Extensive sampling will be done for BTZ-043 at the WK04 visit (Day 28 ± 2 Days) and sparse PK sampling for bedaquiline and delamanid on WK04 (Day 28 ± 2 Days) and WK08 visits (Day 56 ± 2 Days)

    Time frame: Day 28, Day 56

  13. Terminal half-life (t 1/2)

    The pharmacokinetics parameters will be assessed for BTZ-043, bedaquiline and delamanid, and their major metabolites (Arm 2-4), in all participants. Extensive sampling will be done for BTZ-043 at the WK04 visit (Day 28 ± 2 Days) and sparse PK sampling for bedaquiline and delamanid on WK04 (Day 28 ± 2 Days) and WK08 visits (Day 56 ± 2 Days)

    Time frame: Day 28, Day 56

  14. Identification of M. tuberculosis complex and Isoniazid (INH) resistance by PCR (GeneXpert Ultra MTB/RIF®/ GeneXpert XDR/HAIN MTBDRplus or similar)

    Cultures grown from the screening period, and the last sputum sample with mycobacteriological growth will be assessed. This test is qualitative, therefore the result will be: Detected, not detected or indeterminate

    Time frame: Day 01-Day 112

  15. Minimum inhibitory concentrations (MIC) of study drugs the patient was receiving

    Cultures grown from the screening period, and the last sputum sample with mycobacteriological growth will be assessed.

    Time frame: Day 01- Day 112

07

Study locations

4 sites
  • TASK Applied Sciences Clinical Research Centre
    Cape Town, 7500, South Africa
  • TASK Applied Science Eden
    George, 6529, South Africa
  • National Institute for Medical Research (NIMR-MMRC)
    Mbeya, Tanzania
  • National Institute for Medical Research (NIMR-Mwanza),
    Mwanza, Tanzania
08

References and documents

Individual participant data

Plan to share: Yes — Data collected for the study include de-identified individual participant data and a data dictionary defining each field in the set. Which will be made available via C-path

Time frame: Expected in 2032, after decision of licensing application with EMA and FDA

Access criteria: Any researcher can request access, however there are different processes for Unite4TB members and external researchers.

Data sharing details ↗ · c-path.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2024, 15 months.

Of 33 non-industry phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's 15 months is below that.

Counting every sponsor, half of 43 studies reached it within 30 months; a quarter within 21 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2024 → Dec 2024 and completion Aug 2024 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2023
First posted
Jul 3, 2023
StartActual
Sep 21, 2023
Primary completionActual
Dec 27, 2024was Aug 2024
CompletionActual
Dec 27, 2024was Aug 2024
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Primary completion
Aug 2024→Dec 27, 2024 (actual)
Oct 5, 2026
Study completion
Aug 2024→Dec 27, 2024 (actual)
Oct 5, 2026
Enrollment
90 (estimated)→92 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    Primary completion Aug 2024→Dec 27, 2024 (now actual)
    Study completion Aug 2024→Dec 27, 2024 (now actual)
    Enrollment 90 (estimated)→92 (actual)
    + 6 other changes: verification date, criteria formatting, contact details, site details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05926466
Lead sponsor
Michael Hoelscher
Responsible party
Michael Hoelscher (Director, Division for Infectious Diseases and Tropical Medicine, Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
Jul 3, 2023
Start date
Sep 21, 2023
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Last update
Oct 5, 2026

Study contacts

Michael Hoelscher, Prof Dr
study director · LMU University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTZ-043

Start the discussion